Share on facebook
Share on twitter
Share on linkedin

Sickle Cell Disease is said to affect 30 million people worldwide, including 100,000 people in the United States. For most of the world, it is too expensive to diagnose, leading to unnecessary childhood deaths. Even in high-income countries, SCD is hard to monitor and even harder to treat. KovaDx provides an AI-based diagnostic and monitoring device for sickle cell and other hemolytic anemias combining 3D phase imaging with deep learning. The point-of-care device can be influential in low-resource areas by affordable and quick tests. Monitoring also aids in the process of treating and minimizing health care costs.